Paper20008852
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
Milojkovic D and 1 other. Clin Cancer Res, 2009. Cited by 203 papers, by iCite.
Cite this record
ConductScience Library. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Papers, record 20008852. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20008852
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Cited by117
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 203 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943208 | Chronic Myeloid Leukemia Beyond BCR::ABL1 Inhibition: Resistance Mechanisms and Emerging Therapeutic Modalities. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943208 | PubMed |
| 42403636 | Repurposing primaquine diphosphate for imatinib-resistant chronic myeloid leukemia via targeting BCR-ABL and Wnt/β-catenin pathway. | iScience | 2026 | https://conductscience.org/library/papers/42403636 | PubMed |
| 42004278 | CD133-Guided RNA Nanoparticle Delivery of FTO siRNA Impairs Leukemia Resistance to Tyrosine Kinase Inhibitor Therapy. | RNA Nanomed | 2025 | https://conductscience.org/library/papers/42004278 | PubMed |
| 41912913 | BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/41912913 | PubMed |
| 41488007 | Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41488007 | PubMed |
| 41368776 | Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia. | Med Chem | 2025 | https://conductscience.org/library/papers/41368776 | PubMed |
| 41353321 | Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41353321 | PubMed |
| 41203598 | The RNA N6-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signaling. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/41203598 | PubMed |
| 41175949 | Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies. | Semin Cancer Biol | 2025 | https://conductscience.org/library/papers/41175949 | PubMed |
| 41035915 | The role of the lysine histone methylase KMT2D in chronic myeloid leukemia. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41035915 | PubMed |
| 40697388 | ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming. | Front Oncol | 2025 | https://conductscience.org/library/papers/40697388 | PubMed |
| 40627261 | Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40627261 | PubMed |
| 40486167 | Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia. | Leuk Res Rep | 2025 | https://conductscience.org/library/papers/40486167 | PubMed |
| 40283927 | MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40283927 | PubMed |
| 40216016 | Resistance to Allosteric Inhibitors. | J Mol Biol | 2025 | https://conductscience.org/library/papers/40216016 | PubMed |
| 39713537 | Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica. | Adv Lab Med | 2024 | https://conductscience.org/library/papers/39713537 | PubMed |
| 39713534 | T315I - a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia. | Adv Lab Med | 2024 | https://conductscience.org/library/papers/39713534 | PubMed |
| 39518058 | An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39518058 | PubMed |
| 39337925 | Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine. | Life (Basel) | 2024 | https://conductscience.org/library/papers/39337925 | PubMed |
| 39139284 | Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy. | Front Oncol | 2024 | https://conductscience.org/library/papers/39139284 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| BCR | 613 | PubTator's text mining | https://conductscience.org/library/genes/613 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20008852
GET https://conductscience.org/api/papers/v1/20008852/cited_by?page=2